Thrombocytopenias and Thrombocytopathies

From WikiLectures

Hemostasis is the physiological process that prevents excessive bleeding after vascular injury. It depends on intact blood vessels, functional platelets, and normal coagulation factors. Disorders of platelets are broadly divided into thrombocytopenia, which refers to a decreased number of circulating platelets, and thrombocytopathies, which refer to qualitative defects in platelet function despite a normal platelet count. Both conditions predispose patients to abnormal bleeding, especially from mucocutaneous sites.

Thrombocytopenia[edit | edit source]

Thrombocytopenia is defined as a reduction in the peripheral blood platelet count below 150,000/µL. Clinically significant bleeding usually occurs when the platelet count falls below 50,000/µL, while spontaneous bleeding risk increases markedly below 20,000/µL.

Thrombocytopenia develops when platelet homeostasis is disrupted, meaning platelet production, distribution, and destruction are no longer balanced. In normal physiology, platelets are produced by megakaryocytes in the bone marrow under the regulation of thrombopoietin, primarily synthesized in the liver. Therefore, a decrease in platelet count can result from impaired production, increased destruction or consumption, abnormal sequestration, or dilutional effects, and in many clinical conditions, more than one mechanism may coexist.

Decreased Platelet Production

  • Bone marrow aplasia and hypoplasia = In conditions such as aplastic anemia, the bone marrow fails to produce sufficient hematopoietic cells due to stem cell damage, which leads to pancytopenia including thrombocytopenia. This failure may be idiopathic or secondary to drugs, toxins, radiation, or autoimmune destruction of hematopoietic stem cells.
  • Bone marrow infiltration (myelophthisis) = Thrombocytopenia may result when normal bone marrow is replaced by abnormal cells, such as in leukemias, lymphomas, metastatic cancers, or granulomatous diseases. In these cases, megakaryocytes are crowded out, reducing platelet production. The presence of immature or abnormal cells in peripheral blood is part of the diagnosis.
  • Myelodysplastic syndromes = There is ineffective hematopoiesis due to clonal stem cell disorders, leading to the production of abnormal and dysfunctional blood cells. Although megakaryocytes may be present, they produce defective platelets, resulting in both quantitative and qualitative platelet abnormalities.
  • Nutritional deficiencies = Deficiencies of vitamin B12 and folate impair DNA synthesis in rapidly dividing cells, including megakaryocytes, resulting in ineffective platelet production. These conditions often present with megaloblastic anemia and thrombocytopenia.
  • Drug and toxin induced marrow suppression = Many drugs, including chemotherapy agents, chloramphenicol, and some anticonvulsants, can suppress bone marrow activity. Also, alcohol has a direct toxic effect on megakaryocytes and can lead to transient thrombocytopenia. Another example can be radiation exposure that damages hematopoietic tissue.
  • Viral infections affecting marrow = Viruses such as HIV, hepatitis C, Epstein–Barr virus, cytomegalovirus, and parvovirus B19 can infect bone marrow cells or alter the marrow microenvironment, leading to decreased platelet production. In some cases, viral infections also contribute to immune-mediated platelet destruction.
  • Congenital disorders of platelet production = Mostly rare inherited conditions that involve genetic defects in megakaryocyte development, resulting in chronic thrombocytopenia from birth.

Increased Platelet Destruction (Peripheral Loss)

  • Immune-mediated thrombocytopenia = Immune destruction is one of the most common causes of thrombocytopenia.
    • Primary immune thrombocytopenia (ITP) = Autoantibodies, usually IgG, target platelet membrane glycoproteins (usually coated with GP2b/3a and GP2b/9), leading to their destruction primarily in the spleen. Platelet lifespan is significantly shortened, and the bone marrow compensates by increasing megakaryocyte production.
    • Secondary immune thrombocytopenia = Secondary forms occur in association with autoimmune diseases such as systemic lupus erythematosus, infections like HIV or hepatitis C, or lymphoproliferative disorders. The mechanism is similar but triggered by an underlying condition.
  • Drug-induced immune thrombocytopenia = Certain drugs can bind to platelet surfaces and act as haptens, triggering antibody formation. Common offenders include quinine, sulfonamides, penicillin, and rifampicin. Platelet destruction usually resolves after discontinuation of the drug.
  • Heparin-induced thrombocytopenia = An immune-mediated disorder in which antibodies form against complexes of heparin and platelet factor 4, leading to platelet activation, thrombosis, and paradoxical thrombocytopenia.
  • Non-immune platelet destruction (consumptive thrombocytopenia)
    • Disseminated intravascular coagulation = DIC is characterized by widespread activation of the coagulation cascade, leading to formation of microthrombi throughout the circulation. Platelets are consumed in this process, resulting in thrombocytopenia and a high risk of bleeding.
    • Thrombotic thrombocytopenic purpura = TTP is caused by deficiency of ADAMTS13 enzyme, leading to accumulation of large von Willebrand factor multimers that promote platelet aggregation and microthrombi formation, resulting in platelet consumption, hemolytic anemia, and organ ischemia.
    • Mechanical destruction = Platelets can be mechanically destroyed in conditions such as prosthetic heart valves or extracorporeal circulation, where shear stress damages platelets.

Splenic Sequestration (Redistribution)

  • Hypersplenism = The spleen normally stores about one third of the body’s platelets, but in conditions such as liver cirrhosis with portal hypertension, the spleen becomes enlarged and traps a much larger proportion of platelets, resulting in reduced circulating platelet count despite normal production.
  • Liver disease and portal hypertension = Chronic liver disease contributes to thrombocytopenia not only through splenic sequestration but also through reduced thrombopoietin production and possible bone marrow suppression.

Dilution Thrombocytopenia

  • Massive transfusion = In situations such as trauma or major surgery, large volumes of stored red blood cells and fluids are transfused, which lack functional platelets. This dilutes the patient’s circulating platelets and coagulation factors, leading to thrombocytopenia and coagulopathy.

Clinical Features

The clinical manifestations of thrombocytopenia are primarily mucocutaneous. Patients commonly present with petechiae (small pinpoint hemorrhages in the skin), purpura, easy bruising, and ecchymoses. After minor trauma or dental procedures, gingival bleeding, epistaxis, and prolonged bleeding are also frequent. In severe thrombocytopenia, spontaneous bleeding into the gastrointestinal tract, urinary tract, or central nervous system may occur, and intracranial hemorrhage represents the most life-threatening complication.

Laboratory Diagnosis

Complete blood count reveals a decreased platelet count. Peripheral blood smear may show reduced platelet numbers or giant platelets in some disorders such as ITP. Bone marrow examination is useful to distinguish between decreased production and peripheral destruction, where increased megakaryocytes suggest peripheral destruction. Additional tests such as platelet antibody assays, liver function tests, viral markers, and coagulation profiles help identify the underlying cause.

Management

  • Management always depends on the underlying cause, severity of thrombocytopenia, and presence of bleeding
  • Not all patients require treatment; mild, asymptomatic cases may only need observation
  • The risk of bleeding increases significantly when platelet count <50,000/µL, and becomes critical below 20,000/µL

Initial Assessment and Supportive Care

  • Assess for active bleeding (skin, mucosa, internal bleeding)
  • Take a detailed drug history to identify possible drug-induced causes
  • Evaluate for systemic diseases (infection, liver disease, autoimmune disorders)
  • Avoid trauma and invasive procedures when platelet count is low
  • Discontinue antiplatelet drugs (e.g., aspirin, NSAIDs) if possible

Platelet Transfusion

  • Indicated in:
    • Severe thrombocytopenia (<10,000–20,000/µL) even without bleeding
    • Active or life-threatening bleeding (e.g., intracranial, GI bleeding)
    • Before major surgery or invasive procedures
  • Temporary measure, especially useful in acute settings


Management of Immune Thrombocytopenia (ITP)

  • First-line treatment = Corticosteroids (e.g., prednisone) to suppress immune destruction
  • Rapid platelet increase needed = Intravenous immunoglobulin (IVIG)
  • Second-line options (chronic or refractory cases) =
    • Splenectomy (removes major site of platelet destruction)
    • Thrombopoietin receptor agonists (stimulate platelet production)
    • Immunosuppressive agents (e.g., rituximab)

Management of Drug-Induced Thrombocytopenia

  • Immediate discontinuation of the offending drug
  • Platelet count usually recovers within days to weeks
  • Supportive care and transfusion if severe bleeding occurs

Management of Heparin-Induced Thrombocytopenia (HIT)

  • Stop all heparin immediately
  • Start alternative anticoagulation (e.g., direct thrombin inhibitors)
  • Avoid platelet transfusion unless there is severe bleeding

Management of Decreased Production

  • Treat underlying bone marrow disorders =
    • Aplastic anemia → immunosuppressive therapy or bone marrow transplant
    • Leukemia → chemotherapy
  • Correct nutritional deficiencies = Vitamin B12 or folate supplementation
  • Stop marrow-suppressing drugs or toxins (e.g., alcohol)

Thrombocytopathies[edit | edit source]

Thrombocytopathies are disorders characterized by defective platelet function despite a normal platelet count, resulting in impaired primary hemostasis and increased bleeding tendency.

Platelet dysfunction can be divided mechanistically into defects of adhesion, activation, secretion, and aggregation. Adhesion depends on glycoprotein Ib receptors and von Willebrand factor, activation involves intracellular signaling and calcium mobilization, secretion requires intact dense and alpha granules, and aggregation depends on glycoprotein IIb/IIIa receptors binding fibrinogen. Any disruption in these pathways results in defective platelet plug formation and prolonged bleeding.

Inherited thrombocytopathies

Inherited platelet function disorders are rare but clinically significant.

Adhesion defects

In adhesion defects, platelets fail to attach properly to the damaged vascular endothelium. Bernard–Soulier syndrome is a classic example, caused by deficiency or dysfunction of the glycoprotein Ib-IX-V complex, which is required for binding to von Willebrand factor. As a result, platelet adhesion is impaired, and patients present with bleeding tendencies from early life. Platelets are often abnormally large, and thrombocytopenia may also be present.

Aggregation defects

Aggregation defects occur when platelets cannot bind to each other effectively. Glanzmann thrombasthenia is the prototype disorder, caused by deficiency or dysfunction of glycoprotein IIb/IIIa receptors. Without these receptors, fibrinogen cannot form bridges between platelets, leading to severely impaired aggregation despite normal platelet count.

Storage pool disorders

Storage pool disorders involve abnormalities in platelet granules,' particularly dense granules that store ADP, calcium, and serotonin. In these conditions, platelets fail to release mediators necessary for recruitment and amplification of platelet aggregation. This results in mild to moderate bleeding tendencies.

Acquired thrombocytopathies

Acquired disorders are more common than inherited forms.

Drug-induced platelet dysfunction

Many medications interfere with platelet function.

  • Aspirin irreversibly inhibits cyclooxygenase-1, preventing the formation of thromboxane A2, which is essential for platelet activation and aggregation.
  • Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit cyclooxygenase, leading to temporary platelet dysfunction.
  • Antiplatelet drugs such as clopidogrel inhibit ADP receptors (P2Y12), impairing platelet aggregation.

The effect of aspirin lasts for the lifespan of the platelet (7–10 days), whereas NSAIDs have shorter effects.

Uremia

In uremia, accumulation of toxic metabolites interferes with platelet adhesion and aggregation. There is also reduced interaction between platelets and the vessel wall, as well as impaired release of platelet factors. This leads to prolonged bleeding despite normal platelet counts.

Liver disease

In liver disease, platelet dysfunction occurs due to altered synthesis of coagulation factors, abnormal platelet membrane composition, and metabolic disturbances. Additionally, thrombocytopenia from hypersplenism often coexists, worsening bleeding risk.

Myeloproliferative disorders

In conditions such as essential thrombocythemia and polycythemia vera, platelets may be increased in number but are functionally abnormal. This leads to a paradox where patients may experience both thrombosis and bleeding.

Clinical Features

Clinical presentation is similar to thrombocytopenia and includes mucocutaneous bleeding such as petechiae, epistaxis, gingival bleeding, menorrhagia, and excessive bleeding after dental procedures or any other surgeries. However, spontaneous severe internal bleeding is less common compared to severe thrombocytopenia.

Laboratory Diagnosis

Platelet count is normal in thrombocytopathies. Bleeding time is prolonged due to defective platelet function. Coagulation tests such as PT and aPTT are usually normal unless there is associated coagulopathy. Platelet aggregation studies are the standard for diagnosis and help identify specific functional defects.

Management

Management of thrombocytopathies focuses on reducing bleeding risk and correcting underlying causes.

  • Patients are advised to avoid drugs that impair platelet function, such as aspirin and NSAIDs.
  • Desmopressin (DDAVP) may be used in certain conditions to enhance platelet adhesion.
  • Platelet transfusions are used in severe bleeding or before surgical procedures.
  • Antifibrinolytic agents such as tranexamic acid are useful for mucosal bleeding.

References[edit | edit source]

Retrieved from "https://www.wikilectures.eu/index.php?title=Thrombocytopenias_and_Thrombocytopathies&oldid=98523"